Do you still think Recursion Pharmaceuticals Inc (NASDAQ:RXRX) is worth a look?

In yesterday’s Wall Street session, Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares traded at $5.23, up 2.75% from the previous session.

RXRX stock price is now -29.53% away from the 50-day moving average and -35.37% away from the 200-day moving average. The market capitalization of the company currently stands at $1.11B.

With the price target of $8, Morgan Stanley recently initiated with Equal-Weight rating for Recursion Pharmaceuticals Inc (NASDAQ: RXRX).

In other news, Borgeson Blake, Director sold 8,885 shares of the company’s stock on Oct 31. The stock was sold for $46,864 at an average price of $5.27. Upon completion of the transaction, the Director now directly owns 7,416,305 shares in the company, valued at $38.79 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Oct 26, President and COO Larson Tina Marriott sold 3,000 shares of the business’s stock. A total of $16,885 was realized by selling the stock at an average price of $5.63. This leaves the insider owning 418,782 shares of the company worth $2.19 million. Insiders disposed of 1,776,261 shares of company stock worth roughly $9.29 million over the past 1 year. A total of 34.62% of the company’s stock is owned by insiders.

Thursday morning saw Recursion Pharmaceuticals Inc (NASDAQ: RXRX) opened at $5.20. During the past 12 months, Recursion Pharmaceuticals Inc has had a low of $4.54 and a high of $16.75. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 3.72, and a quick ratio of 3.72. The fifty day moving average price for RXRX is $7.34 and a two-hundred day moving average price translates $8.07 for the stock.

The latest earnings results from Recursion Pharmaceuticals Inc (NASDAQ: RXRX) was released for Jun, 2023. According to the Biotechnology Company, earnings per share came in at -$0.38, missing analysts’ expectations of -$0.37 by -0.01. This compares to -$0.38 EPS in the same period last year. The net profit margin was -520.12% and return on equity was -57.36% for RXRX. The company reported revenue of $11.02 million for the quarter, compared to $7.67 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 43.56 percent. For the current quarter, analysts expect RXRX to generate $12.87M in revenue.

Recursion Pharmaceuticals Inc(RXRX) Company Profile

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 1b/2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer; REC-64151 for the treatment of immune checkpoint resistance; and Anti-PD-(L)1, an orally bioavailable small molecule to improve sensitivity to immune checkpoint inhibitors in non-small cell lung cancer and additional tumors. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Related Posts